» Articles » PMID: 18307791

Enkephalin-encoding Herpes Simplex Virus-1 Decreases Inflammation and Hotplate Sensitivity in a Chronic Pancreatitis Model

Overview
Journal Mol Pain
Date 2008 Mar 1
PMID 18307791
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A chronic pancreatitis model was developed in young male Lewis rats fed a high-fat and alcohol liquid diet beginning at three weeks. The model was used to assess time course and efficacy of a replication defective herpes simplex virus type 1 vector construct delivering human cDNA encoding preproenkephalin (HSV-ENK).

Results: Most surprising was the relative lack of inflammation and tissue disruption after HSV-ENK treatment compared to the histopathology consistent with pancreatitis (inflammatory cell infiltration, edema, acinar cell hypertrophy, fibrosis) present as a result of the high-fat and alcohol diet in controls. The HSV-ENK vector delivered to the pancreatic surface at week 3 reversed pancreatitis-associated hotplate hypersensitive responses for 4-6 weeks, while control virus encoding beta-galactosidase cDNA (HSV-beta-gal) had no effect. Increased Fos expression seen bilaterally in pain processing regions in control animals with pancreatitis was absent in HSV-ENK-treated animals. Increased met-enkephalin staining was evident in pancreas and lower thoracic spinal cord laminae I-II in the HSV-ENK-treated rats.

Conclusion: Thus, clear evidence is provided that site specific HSV-mediated transgene delivery of human cDNA encoding preproenkephalin ameliorates pancreatic inflammation and significantly reduces hypersensitive hotplate responses for an extended time consistent with HSV mediated overexpression, without tolerance or evidence of other opiate related side effects.

Citing Articles

Studies on Treatment Within the Scope of Medical Biotechnology for Pancreatic Diseases.

Aylar D, Karatug Kacar A Mol Biotechnol. 2024; .

PMID: 38627328 DOI: 10.1007/s12033-024-01142-5.


Recent Advances in Management of Neuropathic, Nociceptive, and Chronic Pain: A Narrative Review with Focus on Nanomedicine, Gene Therapy, Stem Cell Therapy, and Newer Therapeutic Options.

Kataria S, Patel U, Yabut K, Patel J, Patel R, Patel S Curr Pain Headache Rep. 2024; 28(5):321-333.

PMID: 38386244 PMC: 11126447. DOI: 10.1007/s11916-024-01227-5.


A Mouse Model of Chronic Pancreatitis Induced by an Alcohol and High Fat Diet.

Clinkinbeard T, Kline R, Zhang L, McIlwrath S, Watkins J, Westlund K Open Pain J. 2021; 10(1):81-89.

PMID: 34326907 PMC: 8317824. DOI: 10.2174/1876386301710010081.


Transgene and islet cell delivery systems using nano-sized carriers for the treatment of diabetes mellitus.

Ito K, Ookawara S, Ishibashi K, Morishita Y Nano Rev Exp. 2018; 8(1):1341758.

PMID: 30410709 PMC: 6167029. DOI: 10.1080/20022727.2017.1341758.


Gene Therapy for Pancreatic Diseases: Current Status.

Kamimura K, Yokoo T, Terai S Int J Mol Sci. 2018; 19(11).

PMID: 30384450 PMC: 6275054. DOI: 10.3390/ijms19113415.


References
1.
BRAZ J, Beaufour C, Coutaux A, Epstein A, Cesselin F, Hamon M . Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci. 2001; 21(20):7881-8. PMC: 6763863. View

2.
Walker J . Anti-inflammatory effects of opioids. Adv Exp Med Biol. 2003; 521:148-60. View

3.
Keay K, Clement C, Owler B, Depaulis A, Bandler R . Convergence of deep somatic and visceral nociceptive information onto a discrete ventrolateral midbrain periaqueductal gray region. Neuroscience. 1994; 61(4):727-32. DOI: 10.1016/0306-4522(94)90395-6. View

4.
Schneider A, Whitcomb D, Singer M . Animal models in alcoholic pancreatitis--what can we learn?. Pancreatology. 2002; 2(3):189-203. DOI: 10.1159/000058033. View

5.
Hao S, Mata M, Goins W, Glorioso J, Fink D . Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain. 2003; 102(1-2):135-42. DOI: 10.1016/s0304-3959(02)00346-9. View